China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study for its Omicron-Delta variant recombinant COVID-19 protein vaccine in Uzbekistan. This marks a significant step in the development of the second-generation vaccine, which targets the Omicron and Delta variants.
Previous Clinical Studies
Previously, Zhifei Bio chose Uzbekistan as the first overseas site for the global multi-center Phase III clinical study of its first-generation recombinant COVID-19 vaccine. This vaccine was conditionally approved in China in March of this year. The choice of Uzbekistan for the second-generation vaccine study underscores the country’s role in advancing global vaccine research.
Second-Generation Vaccine Profile
The second-generation recombinant COVID-19 vaccine, co-developed by the Institute of Microbiology, Chinese Academy of Sciences (CAS), is designed to cover the Omicron variants widely distributed at present. It induces a broader and stronger immune response compared to the first-generation recombinant COVID-19 vaccine. This advancement aims to provide enhanced protection against current and emerging variants of the virus.-Fineline Info & Tech
